SLC5A2 and polycythemia: We observed that 16.9% of patients developed erythrocytosis, with a median Hb increase of 1.0 g/dL and Hct increase of 3.5% in our cohort, consistent with recent reports linking SGLT-2 inhibitors to elevated Hb and Hct levels [2, 17].